Eric Larson
Eric R. Larson is a mechanical engineer with over 30 years' experience in plastics. He has helped develop products ranging from boogie boards, water basketball games and SCUBA diving equipment to disposable lighters, cell phones and handheld medical devices. Eric is owner of Art of Mass Production (AMP), an engineering consulting company based in San Diego, CA. AMP provides services to manufacturing companies in the consumer electronics, wireless, and medical device industries. Eric is also moderator of the blog site plasticsguy.com, where he writes about plastics technology and its effect on people and the planet.
ARTICLES BY ERIC LARSON
Medtech Material Selection For Performance And Feel
When designing a medical device, material selection can be difficult, especially with thousands of plastic material options available. While material properties, environmental effects, regulatory requirements, and cost almost always are considered, "feel" is often overlooked – despite its importance to user and patient satisfaction, as well as market success.
Continue Reading..
Medical Plastics: Material Selection Based On Feel
From prioritizing material properties to establishing desired values for each property, selecting plastic materials based on feel is a complicated undertaking. To elicit the most desirable user response from the device, it can be helpful to consider the what, rather than the how.
Continue Reading..
Medbio: Helping To Reduce Supplier Complexity In Drug Delivery Manufacturing
Medbio simplifies drug delivery manufacturing by consolidating tooling, molding, automation, assembly, packaging, and secondary operations under one trusted partner.
Continue Reading..
10.15.26 -- Which Viral Clearance Step Delivers The Highest LRV?
10/15/26 Med Device Online Newsletter
Continue Reading..
10.15.26 -- New Insights For Medical Device Innovation
10/15/26 Med Device Online Newsletter
Continue Reading..
Beyond Australia: Why Medtech Startups Are Re-Evaluating FIH Trial Destinations
The advice handed to medtech companies planning a first-in-human (FIH) study has been: go to Australia. That advice is now overdue for a rewrite. Not because Australia stopped working, but because the math changed.
Continue Reading..
Getting Ahead Of PFAS Risk In Pharmaceutical Manufacturing
Pharma can’t simply eliminate essential PFAS uses. A phased, risk-based strategy can address footprint, exposure, and supply risks amid regulatory uncertainty.
Continue Reading..
PFAS In Medical Devices: What's New And What To Do
Regulators now separate fluoropolymers from other PFAS, but lifecycle risks remain. Readiness starts with knowing which uses, reporting duties, and exposures matter most.
Continue Reading..
A Risk Management Approach For The Pharmaceutical Industry
Replacing fluorinated chemistries across pharma isn’t simple. Growing pressures make it critical to prioritize risks and take a sequenced, evidence-based approach to mitigation.
Continue Reading..
10.13.26 -- New Insights For Medical Device Innovation
10/13/26 Med Device Online Newsletter
Continue Reading..